Prostate Cancer Patients Offered Fresh Hope By Promising New Drug Combination

Prostate Cancer Patients Offered Fresh Hope By Promising New Drug Combination

Prostate Cancer Patients Offered Fresh Hope By Promising New Drug Combination Prostate cancer cells by National Institutes of Health Men with advanced prostate cancer have been offered fresh hope thanks to a “promising” new drug combination. It could significantly delay the progression of a deadly form of the disease in patients with specific genetic mutations, say scientists at University College London following a major international trial. They tested the addition of niraparib, a type of targeted cancer drug known as a PARP inhibitor, to the standard hormone therapy treatment of abiraterone acetate and prednisone, known as AAP. The study focused on patients diagnosed with advanced prostate cancer where cells have spread to other parts of the body, and who were starting their first treatment and also had alterations in genes involved in an essential type of DNA defect repair, known as homologous recombination repair (HRR). Scientists explained that those genes help repair damaged DNA and …